Spots Global Cancer Trial Database for PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Official Title: A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Study ID: NCT01899599
Study Description
Brief Summary: Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.
Detailed Description: The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response after 2nd to 5th line of chemotherapy in patients with epithelial ovarian or fallopian tube or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in a previous line, while the response to the most recent Pt-based chemotherapy must not have lasted more than 12 months. In addition the response between most recent 2 lines of chemotherapy prior start of study medication must not have lasted more than 12 months.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Investigator, Berlin, , Germany
Investigator, Kiel, , Germany
Investigator, Munich, , Germany
Investigator, Munich, , Germany
Investigator, Regensburg, , Germany
Investigator, Stuttgart, , Germany
Investigator, Budapest, , Hungary
Investigator, Debrecen, , Hungary
Investigator, Szeged, , Hungary
Investigator, Meldola, , Italy
Investigator, Milan, , Italy
Investigator, Milan, , Italy
Investigator, Rome, , Italy
Investigator, Bydgoszcz, , Poland
Investigator, Gdansk, , Poland
Investigator, Lublin, , Poland
Investigator, Olsztyn, , Poland
Investigator, Poznan, , Poland
Investigator, Rzeszow, , Poland
Investigator, Brasov, , Romania
Investigator, Bucharest, , Romania
Investigator, Cluj-Napoca, , Romania
Investigator, Cluj-Napoca, , Romania
Investigator, Craiova, , Romania
Investigator, Oradea, , Romania
Investigator, Timisoara, , Romania
Investigator, Timisoara, , Romania
Investigator, Kazan, , Russian Federation
Investigator, Moscow, , Russian Federation
Investigator, Moscow, , Russian Federation
Investigator, Moscow, , Russian Federation
Investigator, Oryol, , Russian Federation
Investigator, Pyatigorsk, , Russian Federation
Investigator, Rostov-on-Don, , Russian Federation
Investigator, St Petersburg, , Russian Federation
Investigator, St. Petersburg, , Russian Federation
Investigator, St. Petersburg, , Russian Federation
Investigator, Volgograd, , Russian Federation
Investigator, Yaroslavl, , Russian Federation
Investigator, Barcelona, , Spain
Investigator, Madrid, , Spain
Investigator, Madrid, , Spain
Investigator, Madrid, , Spain
Investigator, Madrid, , Spain
Investigator, Madrid, , Spain
Investigator, Valencia, , Spain
Investigator, London, , United Kingdom
Investigator, London, , United Kingdom
Investigator, Northwood, , United Kingdom
Investigator, Sutton, , United Kingdom
Contact Details
Name: Jonathan Ledermann, MD
Affiliation: UCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
